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Abstract
Approximately 30–40% of the patients with early stage non-small cell lung cancer (NSCLC) will present with recurrent
disease within two years of resection. Here, we performed extensive galectin expression profiling in a retrospective study
using frozen and paraffin embedded tumor tissues from 87 stage I/II NSCLC patients. Our data show that galectin mRNA
expression in NSCLC is confined to galectin-1, -3, -4, -7, -8, and -9. Next to stage, univariable Cox regression analysis
identified galectin-1, galectin-9FL and galectin-9D5 as possible prognostic markers. Kaplan-Meier survival estimates revealed
that overall survival was significantly shorter in patients that express galectin-1 above median levels, i.e., 23.0 (2.9–43.1) vs.
59.9 (47.7–72.1) months (p = 0.020) as well as in patients that express galectin-9D5 or galectin-9FL below the median, resp.
59.9 (41.9–75.9) vs. 32.8 (8.7–56.9) months (p = 0.014) or 23.2 (20.4–46.8) vs. 58.9 (42.9–74.9) months (p = 0.042). All three
galectins were also prognostic for disease free survival. Multivariable Cox regression analysis showed that for OS, the most
significant prognostic model included stage, age, gal-1 and gal-9D5 while the model for DFS included stage, age and gal-
9D5. In conclusion, the current study confirms the prognostic value of galectin-1 and identifies galectin-9D5 as novel
potential prognostic markers in early stage NSCLC. These findings could help to identify early stage NSCLC patients that
might benefit most from adjuvant chemotherapy.
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Introduction
In non-small cell lung cancer (NSCLC), clinicopathological
staging according to the TNM classification is still the main
delimiter to classify patients with a distinct outcome. Unfortu-
nately, of the patients diagnosed with early stage disease almost
30% to 40% will present tumor recurrence within two years after
surgical resection [1]. Since it has been shown that adjuvant
chemotherapy can improve the survival of patients with resected
stage II-IIIa NSCLC, identification of early stage patients with
poor survival is clinically relevant [1].
Galectins are a protein family of which the members are defined
by the presence of a conserved carbohydrate recognition domain
[2]. Thus far, fifteen galectins have been identified, eleven of
which are also expressed in different human cells and tissues [3,4].
They exert many different functions, with regulation and fine-
tuning of the immune system being the best studied. Consequent-
ly, deregulation of galectin expression is frequently associated with
an inadequate immune response which contributes to different
pathologies, including cancer [5,6]. In addition, galectins have
been found to mediate tumor cell metastasis [7–9] and to induce
and maintain tumor angiogenesis [10–15] which further adds to
cancer progression. All this has resulted in the recognition of
galectins as diagnostic and prognostic markers in different cancer
types, including lung cancer. For example, increased galectin-3
expression has been described as an indicator of poor prognosis in
NSCLC patients [16,17]. Similar observations were reported for
galectin-1 expression [16–18]. Furthermore, galectin-1 expression
is elevated in lung cancer tissue as compared to normal lung [19].
More recently, elevated levels of galectin-1 expression were found
to promote lung cancer progression and chemoresistance [20]
while increased galectin-4 expression was shown to predict lymph
node metastasis in adenocarcinoma of the lung [21]. All these
findings illustrate the prognostic potential of galectins in lung
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cancer. However, whether galectin expression can also be used to
distinguish between early stage NSCLC patients with good or bad
prognosis has not been well established. Therefore, the objective of
this study was to determine whether measurement of galectin
mRNA expression could serve as a predictor of clinical outcome in
patients with stage I/II NSCLC using a multivariable model.
Materials and Methods
Ethical statement
This study was approved by the local internal review
board (Maastricht Pathology Tissue Collection, http://www.
pathologymumc.nl/research/external-projects/maastricht-patho
logy-tissue-collection-mptc) and complies with the recommenda-
tions guiding physicians in biomedical research involving human
subjects as laid down in the Declaration of Helsinki. In accordance
with governing ethics, the use of anonymized tissue from the tissue
bank did not require specific written consent.
Patients
The current study included tumor samples of patients with stage
I/II NSCLC who underwent an anatomic curative resection at the
academic hospital Maastricht between 1994 and 2004 [22].
Exclusion criteria were 1) Previous other malignancy, 2) Devel-
opment of an unrelated malignancy during a follow-up of at least 4
years, or 3) Neo-adjuvant therapy.
Specimen characteristics
Resected material was stored at 280uC as part of the
Maastricht Pathology Tissue Collection. Only tissues from patients
with stage I/II disease and with a tumor area.50% (mean 65.9%,
95%CI: 59.9–71.9), as evaluated in hematoxylin/eosin stained
sections by an experienced pathologist (R-JvS), were considered
eligible for further investigations.
Study design
We retrospectively analyzed tumor tissue from stage I/II
NSCLC patients who underwent curative resection surgery
between 1994 and 2004 at the academic hospital Maastricht. In
total, 87 patients were included. The patients received no prior
treatment and did not have a history of or develop unrelated
malignancies up to 4 years following surgery. The follow-up was at
least 5 years during which the patients were examined routinely
every 3 months the first 2 years and thereafter every 6 months.
Clinical endpoints included overall survival (OS) and disease free
survival (DFS). Overall survival was the time in months from the
day of surgery until the day of death from any cause. Disease free
survival was the time in months from the day of surgery until the
day of tumor recurrence, either locoregional or distant. Candidate
variables that were considered for inclusion in models included the
mRNA expression levels of each galectin (in 2‘-deltaCt), age (in
years), stage (I or II), gender, histology (squamous or other),
smoking status (former or other). The number of patients included
was determined by the availability of tumor samples. Within this
sample size, approximately 50 events occurred which allowed the
inclusion of 5 variables for multivariable analysis to avoid the risk
of over-fitting.
Cell cultures
The following cell lines were used: A549 human alveolar
carcinoma (ATCC CCL-185), H460 human large cell carcinoma
(ATCC HTB-177), H1650 human bronchoalveolar carcinoma
(ATCC CRL-5883), H1975 human non-small cell lung carcinoma
(ATCC CRL-5908), H3255 human non-small cell lung carcinoma
(ATCC CRL-2882, discontinued). All cell lines were cultured in
RPMI (Invitrogen) supplemented with 10% fetal calf serum,
penicillin (50 U/mL) and streptomycin (50 micrograms/mL).
Cells were maintained at 37uC and 5% CO2 in a humidified
incubator.
RNA isolation and cDNA synthesis
Total RNA was isolated from 10610 mm thick frozen tissue
sections or from cultured cells using the RNeasy kit (Qiagen)
according to the manufacturer’s instructions. In case of tumor
tissue, an additional section was taken before and after the series of
10 for H/E staining and evaluation of the percentage of tumor
area. Genomic DNA contamination was removed by on column
DNAse treatment. The concentration and purity of the RNA was
analyzed using the NanoDrop ND-1000 (NanoDrop Technolo-
gies). Subsequently, cDNA synthesis was performed with the
iScript cDNA Synthesis Kit (Biorad) using 0.5 to 1.0 micrograms
of total RNA.
Real-time qPCR
qPCR was performed on an iQ5 Multicolour Real-Time PCR
Detection System (BioRad) or the CFX96 (BioRad) using the iQ
SYBR Green PCR master mix (BioRad) using 400 nmol/L of the
appropriate primers which have been described before [23]. To
distinguish between the different galectin-9 splice variants the
following primers were used: gal-9FL forward GCAGACA-
AAAACCTCCCG, gal-9FL reverse CCCAGAGCACAGGTT-
GATG, gal-9D5 forward ATCAGCTTCCAGCCTCCC, gal-9D5
reverse CCCAGAGCACAGGTTGATG, gal-9D5/6 forward
CTACATCAGCTTCCAGACCCA, gal-9D5/6 reverse CCCA-
GAGCACAGGTTGATG. qPCR for these splice variants was
performed using Sensimix (Quantace) at Tm = 61uC. All primers
were synthesized by Eurogentec.
Western blot
Western blot was performed according to standard protocols. In
brief, 5 to 10 10 mm thick crysections were suspended in 60 mL
Laemlli sample buffer (Biorad) supplemented with 1:20 b-
mercapto-ethanol. Samples were boiled for 5 minutes and
immediately separated by gel electrophoresis on a 15% polyacryl-
amide gel and transferred onto PVDF membranes (Millipore).
Membranes were blocked with Oddyssey blocking buffer (LI-
COR Biosciences) for 1 hour and incubated overnight at 4uC with
either rabbit anti-galectin-1 antibody (Peprotech) or goat anti-
galectin-9 antibody (R&D systems). Loading of the gels was
checked by a-actin detection using mouse anti-a-actin (1:10000,
MP Biomedicals). The membranes were washed three times with
PBS/0.1% tween and subsequently incubated with the appropri-
ate secondary IRDye antibodies (LI-COR Biosciences) at room
temperature for 1 hour. Finally, membranes were washed with
PBS/0.1% tween and rinsed with PBS after which images were
acquired using the Odyssey infrared imaging system (LI-COR
Biosciences).
Immunohistochemistry
Immunohistochemistry for galectin-1 and galectin-9 was per-
formed on paraffin embedded tissue sections according standard
procedures using rabbit anti-galectin-1 (1:500; Peprotech) and goat
anti-galectin-9 (1:500; R&D systems) antibodies of which the
specificity was determined before [23]. Staining were visualized
using the StreptABComplex/HRP kit (Dako). The sections were
counterstained with hematoxylin (Merck), dehydrated, and
mounted in Depex (BDH prolabo). Blinded scoring of galectin-1
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and galectin-9 was performed on three different compartments of
the tumor, i.e. the tumor cells, the tumor stroma, and the tumor
endothelial cells. For scoring of galectin-1 and galectin-9 the
frequency of staining was determined using the following scale:
0 = no or hardly any cells positive,1 = small fraction of cells
positive, 2 = approximately half of the cells positive, 3 = more then
half of the cells positive, 4 = all or the majority of cells positive. All
stainings were scored by at least two independent persons.
Statistical analysis
Bivariable Pearson correlation coefficients were calculated to
study the relationships between galectin mRNA expression levels
(22DCt), clinical parameters, and/or immunohistochemical stain-
ing scores. To identify the most important predictors for patients’
outcome a two-step approach was used. First, univariable
associations between OS or DFS with clinical parameters or each
galectin were examined using Cox regression analysis. Next,
multivariable Cox regression analysis with forward selection was
performed on the most significant galectin predictors identified in
the univariable analysis, i.e. gal-1 (categorical), gal-9FL(categori-
cal), gal-9D5(categorical), together with age (continuous) and stage
(categorical), with either OS or DFS as the outcome. The analysis
included the Kaplan-Meier survival estimates with the Log rank
test were performed to determine median OS or DFS. Median
mRNA expression levels were used as cut-off value to divide the
patients into a high expression group (above median) and low
expression group (below median). Confidence intervals for median
survival were calculated according to Bonnet et al. [24]. All
statistical computations were performed in SPSS20.0.0.
Results
Expression of galectin mRNA in early stage NSCLC and
lung cancer cell lines
We performed extensive galectin gene expression analysis in a
retrospective study on resected tumor tissues derived from 87
patients diagnosed with early stage (stage I/II) NSCLC. The
median age of the patients was 65.5 years (range 37.4–85.5) and
follow-up was at least 5 years during which 47 patients (54.0%)
presented recurrent disease and 50 patients died (57.5%). The
median overall survival (OS), defined as time between day of
surgery until day of death, was 48.7 months (95% CI 33.1–64.2
months). Disease free survival (DFS), defined as time between day
of surgery until day of locoregional or distant recurrence, was 33.3
months (95% CI 34.8–49.6 months). The overall demographic
and standard prognostic variables of the patient group are listed in
Table 1.
To get insight in the prognostic value of galectin expression in
stage I/II NSCLC we first determined which galectins are
expressed in NSCLC tumor tissue. qPCR analysis with previously
validated primers targeted against all known human galectins [23]
revealed that of six galectins, i.e. galectin-1, -3, -4, -7, -8, and -9,
mRNA expression could be detected (Figure 1A). Because
extensive splicing has been reported for galectin-9 [23,25,26], we
also determined the mRNA expression of the most common
galectin-9 splice variants, i.e. galectin-9 full length (FL), galectin-9
with a deletion of exon 5 (D5), and galectin-9 with a deletion of
exons 5 and 6 (D5/6). All three variants were detectable with gal-
9D5 as the dominant variant (Figure 1A, inset). Protein expression
of the different galectin family members was confirmed by
screening immunohistochemical stainings available in the human
protein atlas [27] (Figure 1B). Protein expression of the different
galectin-9 splice isoforms was further confirmed by Western
blot analysis (Figure 1C). Furthermore, expression profiling on
different lung cancer cell lines confirmed that expression was
confined to galectin-1, -3, -4, -7, -8, and -9 (Figure S1). This
corroborates with a study by Lahm et al. who analyzed the
expression of multiple galectins in a broad panel of cancer cell lines
[28]. All these findings show that galectin-1, galectin-3, and
galectin-8 are the most abundantly expressed galectins while the
expression of galectin-4, galectin-7, and galectin-9 is relatively low,
both in tumor tissues and in different lung cancer cell lines.
Relationship between galectin mRNA expression and
clinical parameters in early stage NSCLC
Analysis of the relationship between the different galectin
mRNA expression levels showed a significant positive correlation
between total galectin-9 and the specific galectin-9 splice variants,
i.e. gal-9FL (r = 0.48), gal-9D5 (r = 0.85), and gal-9D5/6 (r = 0.52).
Within these splice variants there was a significant correlation
between gal-9FL and gal-9D5 (r = 0.44) as well as between gal-9D5
and gal-9D5/6 (r = 0.53). Significant correlations were also
observed between galectin-3 and gal-9FL (r = 0.34) and between
gal-4 and gal-9D5/6 (r = 0.31). No significant correlations were
found between the mRNA expression levels of the other galectins.
Regarding the relationship between galectin mRNA expression
and the clinical parameters, i.e. age, stage, gender, histology, and
smoking status, we observed a weakly significant correlation
between gender and gal-9D5 (r = 0.24) and between age and
respectively gal-1 (r = 0.26), gal-9 (r =20.25) and gal-9D5 (r =2
0.30). No significant correlation between galectin mRNA expres-
sion and the remaining parameters, i.e. histology, stage, and
smoking status, was found.
Association between galectin mRNA expression and
prognosis in early stage NSCLC
Next, univariable Cox regression analyses were performed to
select the markers with the strongest association with OS (Table 2)
and DFS (Table 3). This identified stage, gal-1, gal-9FL and gal-
9D5 as possible prognostic factors for both OS and DFS in early
stage NSCLC patients. Subsequently, Kaplan-Meier analyses were
used to estimate median OS and DFS in patients that expressed a
specific galectin below or above the median mRNA expression
level. Patients that expressed galectin-1 above median levels had a
significant shorter OS and DFS (Figure 2A and Table 4). The
univariable Cox model also identified two splice variants of
galectin-9, i.e. gal-9FL and gal-9D5, to be possibly associated with
both OS and DFS. Indeed, patients with either gal-9FL or gal-9D5
expression levels below the median had significant shorter OS as
well as shorter DFS (Figure 2B+C and Table 4). None of the other
galectins was significantly associated with OS or DFS.
Finally, multivariable Cox regression analysis was performed
with forward selection on the most significant factors identified in
the univariable analyses, i.e. stage, age, galectin-1 galctin-9FL and
galectin-9D5. These analyses showed that for OS, the most
significant prognostic model included stage, age, gal-1 and gal-9D5
while the model for DFS included stage, age and gal-9D5
(Table 5).
Localization and distribution of galectin-1 and galectin-9
protein expression in early stage NSCLC tissue
To get more insight in the localization and distribution of
galectin-1 and galectin-9 protein we performed immunohisto-
chemical stainings on a representative subset of tumors (n = 45).
Galectin-1 was widely expressed in most tumor tissues. The
expression in the tumor cells varied between tumors as well as
within tumors, with some tissues showing no positive tumor cells
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while in other tissues the tumor cells were strongly positive. Most
tissues showed positive staining in the stroma as well as in the
tumor endothelial cells (Figure 3A). Galectin-9 staining was less
prominent as compared to galectin-1. In fact, positive tumor cells
were only infrequently observed although some tissues appeared to
display a gradient with increasing galectin-9 levels in the tumor
cells closer to the stromal tissue (Figure 3B). Both the stroma and
the tumor endothelial cells stained positive more frequently
(Figure 3B).
Subsequent Pearson correlation analysis of the staining scores
showed that there was a significant inverse correlation between the
score of galectin-1 and galectin-9 in the tumor cells (corr. coef. 2
0.36) while there was a positive correlation between galectin-1 and
galectin-9 protein score in the tumor endothelial cells (corr. coef.
0.44). However, neither the galectin-1 or galectin-9 protein
staining scores were associated with OS or DFS. Furthermore,
there was no correlation between IHC scores and mRNA levels.
Discussion
We evaluated the prognostic significance of galectin mRNA
expression in patients with stage I/II non-small cell lung cancer.
Univariable Cox regression analyses were used to select a set of the
most prognostic clinical parameters and galectins. These were
subsequently used in a multivariable analysis to generate a model
that could serve to predict OS or DFS in patients with stage I/II
NSCLC. The main finding of this study is that for predicting OS,
the most significant prognostic model included stage, age, gal-1
and gal-9D5 while the model for DFS included stage, age and gal-
9D5.
Galectins have previously been associated with lung cancer
progression [16,17,29]. Our observation that patients that express
galectin-1 above median levels have a significant shorter overall is
in agreement with these studies [16,17] as well as with studies in
other types of cancer [30]. The prognostic value of galectin-1 was
Table 1. Patient characteristics.
Total number of patients 87







Large cell 12 (13.8%)
Stage
Stage IA 11 (12.6%)
Stage IB 44 (50.6%)
Stage IIA 6 (6.9%)









Median OS (months; 95% CI) 48.7 (39.6–53.6)
Events (death) 50 (57.5%)
Median DFS (months; 95% CI) 33.3 (34.8–49.6)
Events (recurrence) 47 (54.0%)
doi:10.1371/journal.pone.0107988.t001
Figure 1. Galectin mRNA expression profile in tumor tissues
obtained from early stage non-small cell lung cancer patients
(n- = 87) (A). The inset shows the expression of the three galectin-9
splice variants. (B) Images of immunohistochemical staining of the
galectins with detectable mRNA expression in NSCLC [27]. (C) Western
blot analysis of galectin-9 isoform expression in NSCLC tumor tissue
from 5 different patients. Three bands at expected molecular weights of
galectin-9FL, galectin-9D5 and galectin-9D5/6 were observed at varying
intensities.
doi:10.1371/journal.pone.0107988.g001
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confirmed in the multivariable analysis. Galectin-3, which has also
been associated with poor disease outcome in lung cancer patients
[16,17], did not reach statistical significance in our patient group.
This corroborates with two more recent studies [31,32]. On the
other hand, it has been suggested that cellular localization of
galectin-3, i.e. nuclear vs. cytoplasmic might be of prognostic value
for recurrence [33]. We only measured galectin-3 mRNA
expression levels and did not determine the cellular localization
of galectin-3 protein expression in our patient group. Thus, we
cannot exclude that these parameters could be of prognostic value
in stage I/II NSCLC patients.
A novel finding of the current study was the identification of a
specific gal-9 splice variant, i.e. galectin-9D5 as a prognostic
marker in NSCLC. Using multivariable Cox regression analysis
we now observed that low galectin-9D5 expression was associated
with poor OS and DFS in early stage NSCLC patients. These
observations are in line with other reports in which galectin-9
expression was inversely correlated with cancer progression and
patient survival in a number of different cancer types, including
skin cancer, liver cancer, and breast cancer [34–36]. More
recently, Jiang et al. identified galectin-9 expression as an
independent prognostic factor in a retrospective study on 305
Table 2. Univariable analyses of standard clinical variables and galectin mRNA expression levels in relation to overall survival in 87
patients with early stage NSCLC.
HR 95% CI p-value
Age 1.03 1.00 to 1.06 0.064
Gender 0.71 0.37 to 1.40 0.325
Stagea 1.91 1.09 to 3.35 0.024
Histologyb 0.76 0.44 to 1.33 0.340
Smoking statusc 1.30 0.70 to 2.42 0.402
Gal1d 1.94 1.10 to 3.41 0.022
Gal3d 0.60 0.34 to 1.05 0.071
Gal4d 0.68 0.39 to 1.18 0.170
Gal7d 0.96 0.53 to 1.74 0.899
Gal8d 0.78 0.45 to 1.36 0.383
Gal9d 0.76 0.44 to 1.33 0.333
Gal9FLd 0.54 0.30 to 0.99 0.045
Gal9d5d 0.48 0.26 to 0.87 0.016
Gal9d56d 0.73 0.41 to 1.32 0.304
a)Stage I vs. stage II, b)Squamous vs. others, c)Former smoker vs. others, d)Above vs. below median mRNA expression
doi:10.1371/journal.pone.0107988.t002
Table 3. Univariable analyses of standard clinical variables and galectin mRNA expression levels in relation to disease free survival
in 87 patients with early stage NSCLC.
HR 95% CI p-value
Age 1.02 1.02 to 0.99 0.150
Gender 0.76 0.76 to 0.39 0.426
Stagea 1.95 1.95 to 1.11 0.021
Histologyb 0.80 0.80 to 0.46 0.425
Smoking statusc 1.34 1.34 to 0.72 0.357
Gal1d 1.78 1.78 to 1.01 0.046
Gal3d 0.58 0.58 to 0.33 0.059
Gal4d 0.71 0.71 to 0.41 0.231
Gal7d 0.89 0.89 to 0.49 0.700
Gal8d 0.79 0.79 to 0.45 0.403
Gal9d 0.76 0.76 to 0.44 0.336
Gal9FLd 0.54 0.54 to 0.30 0.044
Gal9d5d 0.48 0.48 to 0.26 0.017
Gal9d56d 0.72 0.72 to 0.40 0.283
a)Stage I vs. stage II, b)Squamous vs. others, c)Former smoker vs. others, d)Above vs. below median mRNA expression
doi:10.1371/journal.pone.0107988.t003
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patients with gastric cancer. Again, low galectin-9 expression was
associated with poor survival [37].
Galectin-9D5 is one of the three most frequently identified
galectin-9 variants. These splice variants encode protein isoforms
that vary in the length of the linker region between the two CRD
domains which affects multimer formation and valency [38,39].
Previous data suggest that the different galectin-9 isoforms have a
diverging role in tumor cells, e.g. they differently affect the
adhesion of cells to the ECM and to the endothelium [40]. In
general, altered galectin-9 expression has been linked to abnormal
cell adhesion, growth and migration [39]. Others have described
that galectin-9 can influence cell survival as well as homo- and
Figure 2. Kaplan-Meier plots of overall survival (OS) or disease free survival (DFS) in early stage NSCLC patients with low (Lo: below
median) or high (Hi: above median) expression of galectin-1 (A), galectin-9FL (B) and galectin-9D5 (C).
doi:10.1371/journal.pone.0107988.g002
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heterotypic cell aggregation [9,34,40–43]. Loss of galectin-9
expression could compromise tissue integrity allowing tumor cells
to intravasate into circulation and metastasize. Indeed, in breast
cancer low galectin-9 expression was a better predictor of distant
metastasis compared to lymph node status [42]. Similar observa-
tions were made in melanoma and cervical squamous cell
carcinoma [34,44]. However, these effects depend on multiple
parameters, including the specific galectin-9 variant, the type of
cell and the adhesion matrix component to which the cells bind
[45]. Whether and how all these parameters influence lung cancer
progression requires further studies. Possibly, galectin-9 can act as
a chemoattractant for lung cancer cells, similar as described for
eosinophils [46,47] or endothelial cells [26]. Together with our
observation that stromal galectin-9D5 expression remains elevated
in lung tumors this chemoattracting activity indicates that galectin-
9D5 might act as a guidance cue for metastatic tumor cells to
migrate towards the site of intravasation, i.e. the vasculature. This
could promote tumor metastasis especially if loss of galectin-9 in
tumor cells results in loss of tissue integrity [45]. Finally, it has
been reported that in animal models and cancer patients, tumor
cells can release galectin-9 containing exosomes that can induce T-
cell apoptosis [48,49]. Whether tumor endothelial cells also secrete
Table 4. Kaplan-Meier estimates of median OS and DFS in early stage NSCLC patients with galectin expression below or above the
median level.
Median OS (95% CI) in months Median DFS (95% CI) in months
Lowa expression High expression P Lowa expression High expression P
Gal-1 59.9 (47.7–72.1) 23.0 (2.9–43.1) 0.020 55.5 (35.7–75.3) 20.8 (21.35–43.0) 0.043
Gal-3 28.0 (5.3–50.6) 58.9 (44.5–73.3) 0.068 16.6 (25.8–39.0) 58.1 (39.3–76.9) 0.055
Gal-4 33.2 (10.1–56.3) 57.5 (41.8–73.1) 0.167 22.4 (21.9–46.6) 54.7 (31.3–78.1) 0.228
Gal-7 57.3 (36.6–78.0) 52.5 (29.5–75.5) 0.899 43.2 (19.9–66.5) 49.7 (25.0–74.4) 0.699
Gal-8 40.7 (21.6–59.8) 56.3 (33.9–78.7) 0.382 27.8 (6.4–49.1) 55.0 (30.9–79.1) 0.402
Gal-9 42.6 (20.4–64.8) 56.3 (40.85–71.8) 0.331 23.9 (21.7–49.4) 54.7 (34.7–74.7) 0.334
Gal-9FL 23.2 (20.4–46.8) 58.9 (42.9–74.9) 0.042 20.9 (2.8–39.1) 58.1 (37.4–78.8) 0.040
Gal-9D5 32.8 (8.7–56.9) 59.9 (41.9–75.9) 0.014 20.9 (22.5–44.3) 58.1 (36.4–79.8) 0.014
Gal-9D5/6 39.3 (16.8–61.8) 58.6 (42.0–75.2) 0.302 23.8 (20.9–48.2) 54.7 (30.0–79.4) 0.280
HR= hazard ratio; CI = confidence interval.
doi:10.1371/journal.pone.0107988.t004
Table 5. Multivariate Cox regression analysis with forward selection.
Overall survival
Variables in the Equation HR 95% CI p-value overall p-value
Step 1 age 1.05 1.01 to 1.09 0.009 0.008
Step 2 stageI_II 2.41 1.32 to 4.43 0.004 0.001
age 1.06 1.02 to 1.10 0.002
Step 3 stageI_II 2.10 1.14 to 3.87 0.018 0.000185
age 1.06 1.02 to 1.10 0.003
gal9d5 0.52 0.28 to 0.97 0.039
Step 4 stageI_II 2.41 1.30 to 4.49 0.006 0.000099
age 1.05 1.01 to 1.10 0.008
gal1 2.08 1.09 to 3.97 0.026
gal9d5 0.46 0.24 to 0.85 0.013
Disease free survival
Variables in the Equation HR 95% CI p-value overall p-value
Step 1 gal9d5 0.48 0.26 to 0.88 0.017 0.014
Step 2 age 1.05 1.01 to 1.09 0.016 0.003
gal9d5 0.47 0.25 to 0.85 0.013
Step 3 stageI_II 2.08 1.12 to 3.87 0.021 0.000472
age 1.05 1.01 to 1.10 0.007
gal9d5 0.54 0.29 to 1.00 0.051
HR= hazard ratio; CI = confidence interval.
doi:10.1371/journal.pone.0107988.t005
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galectin-9 containing exosomes needs to be further investigated,
but such a mechanism could contribute to tumor progression by
providing a way to escape immune surveillance.
Immunohistochemical assessment of galectin-1 and galectin-9
protein expression showed differences in the localization and
distribution within the tumor tissue. These observations are in line
with previous findings in different tumors where both galectin-1
and galectin-9 proteins could be detected in different compart-
ments of the tumor, including tumor cells, tumor stroma and
tumor endothelial cells [17,23,30,42,44]. Nevertheless, protein
expression had no prognostic value in our patient group. Most
likely, this is related to the fact that immunohistochemical staining
represents a more qualitative evaluation rather than a quantitative
analysis. Thus, actual protein expression levels could not be
accurately quantified by IHC staining. Furthermore, no galectin-9
antibodies are available that recognize specific splice variants. This
suggests that in case of early stage NSCLC patients, determining
galectin mRNA levels is of more value for prognosis estimates as
compared to immunohistochemical staining.
The main limitation of the present study is the relatively low
sample size of 87 in relation to the large number of parameters
that was analyzed. The sample size allowed the inclusion of only 5
covariates in the regression model to minimize the risk of over-
fitting. In addition, we only included early stage NSCLC patients.
Thus, additional studies using larger patient groups and also
including later stages of NSCLC, i.e. stage III/IV, might provide
more insight in the prognostic value of galectin mRNA expression
profiling.
In summary, extensive galectin expression profiling confirmed
the prognostic value of galectin-1 and identified gal-9D5 as a
potential novel prognostic markers in early stage NSCLC.
Identification of such markers is important to identify patients
that will benefit from adjuvant chemotherapy. In addition, our
findings exemplify the relevance of profiling individual splice
variants of galectin-9. It remains to be determined whether splice
variant-specific profiling has a similar benefit in other cancer types,
including those in which overall galectin-9 expression is a
prognostic marker.
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